372 related articles for article (PubMed ID: 16474521)
21. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database.
Moreira DM; Jayachandran J; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Stephenson AJ; Freedland SJ
BJU Int; 2009 Nov; 104(10):1452-6. PubMed ID: 19466946
[TBL] [Abstract][Full Text] [Related]
22. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.
Murat FJ; Poissonnier L; Rabilloud M; Belot A; Bouvier R; Rouviere O; Chapelon JY; Gelet A
Eur Urol; 2009 Mar; 55(3):640-7. PubMed ID: 18508188
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
24. Late toxicity after postprostatectomy salvage radiation therapy.
Peterson JL; Buskirk SJ; Heckman MG; Crook JE; Ko SJ; Wehle MJ; Igel TC; Prussak KA; Pisansky TM
Radiother Oncol; 2009 Nov; 93(2):203-6. PubMed ID: 19766337
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
[TBL] [Abstract][Full Text] [Related]
26. Salvage options for biochemical recurrence after primary therapy for prostate cancer.
Bong GW; Keane TE
Can J Urol; 2007 Dec; 14 Suppl 1():2-9. PubMed ID: 18163938
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy for locally recurrent prostate cancer.
Kirkpatrick JP; Anscher MS
Clin Adv Hematol Oncol; 2005 Dec; 3(12):933-42. PubMed ID: 16555435
[TBL] [Abstract][Full Text] [Related]
28. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
[TBL] [Abstract][Full Text] [Related]
29. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
[TBL] [Abstract][Full Text] [Related]
30. Rising prostate-specific antigen after primary prostate cancer therapy.
Ward JF; Moul JW
Nat Clin Pract Urol; 2005 Apr; 2(4):174-82. PubMed ID: 16474760
[TBL] [Abstract][Full Text] [Related]
31. [Rising Prostate Specific Antigen following treatment with curative intention].
Jakobsen H; Pedersen KV
Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy.
Niehoff P; Loch T; Nürnberg N; Galalae R; Egberts J; Kohr P; Kovács G
Brachytherapy; 2005; 4(2):141-5. PubMed ID: 15893268
[TBL] [Abstract][Full Text] [Related]
33. [Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: comparisons among ASTRO and Phoenix biochemical failure definitions].
Quero L; Mongiat-Artus P; Ravery V; Hennequin V; Maylin C; Desgrandchamps F; Hennequin C
Cancer Radiother; 2009 Jul; 13(4):267-75. PubMed ID: 19446487
[TBL] [Abstract][Full Text] [Related]
34. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
[TBL] [Abstract][Full Text] [Related]
35. An algorithm for managing the failure of external beam radiotherapy in prostate cancer.
Dudderidge T; Payne H; Emberton M
BJU Int; 2007 Sep; 100(3):518-27. PubMed ID: 17573894
[TBL] [Abstract][Full Text] [Related]
36. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
37. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
38. [Diagnostic methodology for the biochemical recurrence of prostate cancer after radical prostatectomy].
Serra AC; Narbón ES
Arch Esp Urol; 2006 Dec; 59(10):1041-52. PubMed ID: 17283717
[TBL] [Abstract][Full Text] [Related]
39. Sequential treatment for recurrent localized prostate cancer.
Van Der Poel HG; Moonen L; Horenblas S
J Surg Oncol; 2008 Apr; 97(5):377-82. PubMed ID: 18360820
[TBL] [Abstract][Full Text] [Related]
40. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
